We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CAH Posts Strong Cash Flow, Eyes Next Steps in Capital Deployment
Read MoreHide Full Article
Key Takeaways
Cardinal Health generated $1.8B in adjusted free cash flow, boosting capital allocation flexibility.
CAH returned $1B to shareholders via $750M buybacks and $250M dividends while funding $240M in capex.
CAH improved leverage to 3.2x and eyes reinvestment, bolt-on deals, and growth in specialty segments.
Cardinal Health’s (CAH - Free Report) strong cash generation in fiscal 2026 is providing the company with increasing flexibility to execute a disciplined and balanced capital allocation strategy. Year to date, CAH has generated approximately $1.8 billion in adjusted free cash flow, reflecting robust operating performance, favorable working capital dynamics and continued earnings momentum across its portfolio.
A significant portion of this cash has already been deployed toward shareholder returns. CAH returned roughly $1 billion to shareholders, including $750 million in share repurchases and $250 million in dividends, underscoring management’s commitment to delivering near-term value while maintaining financial discipline. At the same time, the company continues to reinvest in the business, with about $240 million allocated to capital expenditures supporting organic growth initiatives.
CAH has strengthened its balance sheet, with its leverage ratio returning to 3.2x, comfortably within the targeted range of 2.75x to 3.25x. Achieving this milestone ahead of schedule enhances financial flexibility and enables management to evaluate incremental capital deployment opportunities without compromising balance sheet integrity.
CAH is signaling a measured and opportunistic approach. Management emphasized that capital deployment will continue to follow a disciplined framework, balancing reinvestment in high-growth areas such as specialty, MSO platforms, and biopharma services with potential incremental returns to shareholders.
While large-scale M&A is not a strategic necessity, the company remains open to targeted, bolt-on acquisitions, particularly in fragmented areas like at-Home Solutions and specialty services, where synergies and capability expansion are evident.
Overall, CAH’s strong free cash flow profile, improved leverage position and diversified growth platform position it to deploy capital strategically, supporting both sustained earnings growth and long-term shareholder value creation.
Peer Update
Align Technology (ALGN - Free Report) demonstrated a disciplined capital allocation approach anchored in strong cash generation and balance sheet flexibility. The company ended 2025 with more than $1.09 billion in cash, providing ample liquidity to fund growth and shareholder returns. It deployed $465.9 million toward share repurchases during 2025, with a sizable authorization still available, signaling confidence in long-term value creation.
ALGN continues to reinvest in manufacturing capacity, digital platforms, and AI-driven workflows, balancing buybacks with growth investments. This dual-track strategy enhances operating leverage while maintaining strategic flexibility.
CONMED (CNMD - Free Report) is reshaping its capital allocation strategy to prioritize higher-return growth platforms while maintaining balance sheet discipline. The company has reduced leverage to 2.9x, enhancing financial flexibility and positioning it to support innovation and expansion initiatives.
CNMD has suspended its dividend and redirected capital toward share repurchases, with a $150 million authorization, reflecting a shift toward more accretive capital deployment. It is also reallocating resources following its GI exit, focusing investments on high-growth areas, such as orthopedics and minimally invasive surgery. This targeted approach underscores CONMED’s intent to optimize its balance sheet while driving earnings growth.
CAH’s Price Performance, Valuation and Estimates
Shares of CAH have surged 42.4% over the past six months compared with the industry’s 14.4% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, Cardinal Health trades at a forward price-to-earnings ratio of 19.09, above the industry average. It is also higher than its five-year median of 13.47. CAH carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Cardinal Health’s fiscal 2026 earnings implies a 25.1% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Bigstock
CAH Posts Strong Cash Flow, Eyes Next Steps in Capital Deployment
Key Takeaways
Cardinal Health’s (CAH - Free Report) strong cash generation in fiscal 2026 is providing the company with increasing flexibility to execute a disciplined and balanced capital allocation strategy. Year to date, CAH has generated approximately $1.8 billion in adjusted free cash flow, reflecting robust operating performance, favorable working capital dynamics and continued earnings momentum across its portfolio.
A significant portion of this cash has already been deployed toward shareholder returns. CAH returned roughly $1 billion to shareholders, including $750 million in share repurchases and $250 million in dividends, underscoring management’s commitment to delivering near-term value while maintaining financial discipline. At the same time, the company continues to reinvest in the business, with about $240 million allocated to capital expenditures supporting organic growth initiatives.
CAH has strengthened its balance sheet, with its leverage ratio returning to 3.2x, comfortably within the targeted range of 2.75x to 3.25x. Achieving this milestone ahead of schedule enhances financial flexibility and enables management to evaluate incremental capital deployment opportunities without compromising balance sheet integrity.
CAH is signaling a measured and opportunistic approach. Management emphasized that capital deployment will continue to follow a disciplined framework, balancing reinvestment in high-growth areas such as specialty, MSO platforms, and biopharma services with potential incremental returns to shareholders.
While large-scale M&A is not a strategic necessity, the company remains open to targeted, bolt-on acquisitions, particularly in fragmented areas like at-Home Solutions and specialty services, where synergies and capability expansion are evident.
Overall, CAH’s strong free cash flow profile, improved leverage position and diversified growth platform position it to deploy capital strategically, supporting both sustained earnings growth and long-term shareholder value creation.
Peer Update
Align Technology (ALGN - Free Report) demonstrated a disciplined capital allocation approach anchored in strong cash generation and balance sheet flexibility. The company ended 2025 with more than $1.09 billion in cash, providing ample liquidity to fund growth and shareholder returns. It deployed $465.9 million toward share repurchases during 2025, with a sizable authorization still available, signaling confidence in long-term value creation.
ALGN continues to reinvest in manufacturing capacity, digital platforms, and AI-driven workflows, balancing buybacks with growth investments. This dual-track strategy enhances operating leverage while maintaining strategic flexibility.
CONMED (CNMD - Free Report) is reshaping its capital allocation strategy to prioritize higher-return growth platforms while maintaining balance sheet discipline. The company has reduced leverage to 2.9x, enhancing financial flexibility and positioning it to support innovation and expansion initiatives.
CNMD has suspended its dividend and redirected capital toward share repurchases, with a $150 million authorization, reflecting a shift toward more accretive capital deployment. It is also reallocating resources following its GI exit, focusing investments on high-growth areas, such as orthopedics and minimally invasive surgery. This targeted approach underscores CONMED’s intent to optimize its balance sheet while driving earnings growth.
CAH’s Price Performance, Valuation and Estimates
Shares of CAH have surged 42.4% over the past six months compared with the industry’s 14.4% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, Cardinal Health trades at a forward price-to-earnings ratio of 19.09, above the industry average. It is also higher than its five-year median of 13.47. CAH carries a Value Score of B.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Cardinal Health’s fiscal 2026 earnings implies a 25.1% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.